CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons Learned
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- March 21, 2012
has subject area
- 1112 Oncology and Carcinogenesis (FoR)
- Antineoplastic Agents, Hormonal (MeSH)
- Breast Neoplasms (MeSH)
- Cytochrome P-450 CYP2D6 (MeSH)
- Female (MeSH)
- Glucuronosyltransferase (MeSH)
- Humans (MeSH)
- Letrozole (MeSH)
- Neoplasm Recurrence, Local (MeSH)
- Nitriles (MeSH)
- Oncology & Carcinogenesis (Science Metrix)
- Polymorphism, Single Nucleotide (MeSH)
- Postmenopause (MeSH)
- Tamoxifen (MeSH)
- Triazoles (MeSH)